JP2016525548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525548A5 JP2016525548A5 JP2016529872A JP2016529872A JP2016525548A5 JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5 JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016525548 A5 JP2016525548 A5 JP 2016525548A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- desmopressin
- combination medicament
- hours
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857431P | 2013-07-23 | 2013-07-23 | |
| US61/857,431 | 2013-07-23 | ||
| PCT/US2014/047899 WO2015013454A1 (en) | 2013-07-23 | 2014-07-23 | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065913A Division JP7219736B2 (ja) | 2013-07-23 | 2020-04-01 | Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525548A JP2016525548A (ja) | 2016-08-25 |
| JP2016525548A5 true JP2016525548A5 (enExample) | 2017-08-31 |
Family
ID=51299056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529872A Pending JP2016525548A (ja) | 2013-07-23 | 2014-07-23 | Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| JP2020065913A Active JP7219736B2 (ja) | 2013-07-23 | 2020-04-01 | Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065913A Active JP7219736B2 (ja) | 2013-07-23 | 2020-04-01 | Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9814753B2 (enExample) |
| EP (1) | EP3024474B1 (enExample) |
| JP (2) | JP2016525548A (enExample) |
| KR (3) | KR20240015735A (enExample) |
| CN (1) | CN105579057A (enExample) |
| AU (1) | AU2014293141A1 (enExample) |
| CA (1) | CA2919198A1 (enExample) |
| DK (1) | DK3024474T3 (enExample) |
| ES (1) | ES2910361T3 (enExample) |
| MX (1) | MX2016001030A (enExample) |
| WO (1) | WO2015013454A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| CA2765221C (en) * | 2009-06-18 | 2017-10-03 | Allergan, Inc. | Safe desmopressin administration |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| EP3024473A1 (en) | 2013-07-23 | 2016-06-01 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| CA2967390A1 (en) | 2014-11-20 | 2016-05-26 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
| MX2017007054A (es) | 2014-12-03 | 2018-05-02 | Velicept Therapeutics Inc | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. |
| WO2017210700A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| KR101877834B1 (ko) * | 2017-04-27 | 2018-07-12 | 주식회사 다산제약 | 미라베그론의 신규한 염 및 이의 제조방법 |
| CN112587508A (zh) * | 2020-12-20 | 2021-04-02 | 北京君和为医药科技有限公司 | 一种米拉贝隆透皮贴剂 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| NZ241979A (en) | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| WO1999027905A1 (en) | 1997-12-02 | 1999-06-10 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Compositions for nasal administration |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| WO2002055128A2 (en) | 2000-11-30 | 2002-07-18 | Biovalve Technologies Inc | Fluid delivery and measurement systems and methods |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| CA2503570C (en) * | 2002-11-07 | 2011-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| WO2005046707A1 (en) | 2003-11-10 | 2005-05-26 | Fein Seymour H | Pharmaceutical compositions including low dosages of desmopressin |
| JP2007513199A (ja) | 2003-12-08 | 2007-05-24 | ベントレー ファーマスーティカルス，インコーポレイテッド | インスリン治療のための薬学的組成物及び方法 |
| DE102005016981A1 (de) | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| WO2007072156A1 (en) | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
| JPWO2007083640A1 (ja) * | 2006-01-18 | 2009-06-11 | 杏林製薬株式会社 | 頻尿及び尿失禁の予防又は治療剤 |
| WO2009021007A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
| CN101648017A (zh) | 2008-08-12 | 2010-02-17 | 许洁 | 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物 |
| WO2010028211A1 (en) | 2008-09-04 | 2010-03-11 | Rozmanith Anthony I | Health care |
| SG10201509152VA (en) * | 2008-12-22 | 2015-12-30 | Allergan Inc | Intranasal desmopressin administration |
| US20100160214A1 (en) | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
| CA2765221C (en) * | 2009-06-18 | 2017-10-03 | Allergan, Inc. | Safe desmopressin administration |
| US20120202819A1 (en) * | 2009-10-07 | 2012-08-09 | Merck Sharp & Dohme Corporation | Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent |
| US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US9522129B2 (en) * | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| EP2907504B1 (en) | 2011-02-08 | 2017-06-28 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| NZ712594A (en) | 2012-03-19 | 2016-09-30 | Wellesley Pharmaceuticals Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| GB201312155D0 (en) | 2013-07-05 | 2013-08-21 | Ucl Business Plc | Therapeutic invention |
| CN105579057A (zh) | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| EP3024473A1 (en) | 2013-07-23 | 2016-06-01 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| US20160220489A1 (en) | 2013-09-03 | 2016-08-04 | G2B Pharma Inc. | Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions |
| CA2967390A1 (en) | 2014-11-20 | 2016-05-26 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
-
2014
- 2014-07-23 CN CN201480052301.7A patent/CN105579057A/zh active Pending
- 2014-07-23 AU AU2014293141A patent/AU2014293141A1/en not_active Abandoned
- 2014-07-23 MX MX2016001030A patent/MX2016001030A/es unknown
- 2014-07-23 US US14/338,554 patent/US9814753B2/en not_active Expired - Fee Related
- 2014-07-23 EP EP14748451.3A patent/EP3024474B1/en active Active
- 2014-07-23 JP JP2016529872A patent/JP2016525548A/ja active Pending
- 2014-07-23 KR KR1020247002750A patent/KR20240015735A/ko not_active Ceased
- 2014-07-23 ES ES14748451T patent/ES2910361T3/es active Active
- 2014-07-23 WO PCT/US2014/047899 patent/WO2015013454A1/en not_active Ceased
- 2014-07-23 DK DK14748451.3T patent/DK3024474T3/da active
- 2014-07-23 CA CA2919198A patent/CA2919198A1/en active Pending
- 2014-07-23 KR KR1020167004515A patent/KR20160033220A/ko not_active Ceased
- 2014-07-23 KR KR1020217025792A patent/KR20210103589A/ko not_active Ceased
-
2017
- 2017-11-13 US US15/811,384 patent/US10568927B2/en active Active
-
2020
- 2020-04-01 JP JP2020065913A patent/JP7219736B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| JP2016185995A5 (enExample) | ||
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| JP2016539921A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2016519107A5 (enExample) | ||
| JP2019514990A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja | |
| JP2014520874A5 (enExample) | ||
| JP2020500930A5 (enExample) | ||
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| JP2016525147A5 (enExample) | ||
| KR101896441B1 (ko) | 국소투여형의 연하장애 개선용 의약품 | |
| JP2016504361A5 (enExample) | ||
| MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. | |
| JP2015515971A5 (enExample) | ||
| JP2010526884A5 (enExample) | ||
| JP2013542262A5 (enExample) | ||
| JP2017513866A5 (enExample) | ||
| JP2015516451A5 (enExample) |